Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04520607 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
A Phase 3 study, sponsored by Biosplice Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
NCT04520607 is a Phase 3 study that was terminated before completion, run by Biosplice Therapeutics. The registered enrollment target is 276 participants.
The verdict
NCT04520607, a Phase 3 study, was terminated before completion, sponsored by Biosplice Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
Study Summary
Study OA-07 was a randomized, double-blind, placebo-controlled, Phase 3, multicenter, 2-year clinical trial that enrolled subjects from the recently completed Study OA-11 (NCT03928184). The first 48 weeks of OA-07 the trial was placebo-controlled with subjects receiving the same randomized treatment received in OA-11. Investigators, research staff and subjects remained blinded to treatment allocation. At Week 48, all subjects were administered LOR in the open-label portion of the trial.
Interventions
- DRUG Placebo
- DRUG Lorecivivint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04520607
The ClinicalTrials.gov registry entry for NCT04520607 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04520607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04520607 about?
NCT04520607 is a clinical study titled "A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee". Study OA-07 was a randomized, double-blind, placebo-controlled, Phase 3, multicenter, 2-year clinical trial that enrolled subjects from the recently completed Study OA-11 (NCT03928184). The first 48 weeks of OA-07 the trial was placebo-controlled with subjects receiving the same randomized treatmen...
What is the current status of trial NCT04520607?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2020-08-25. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT04520607?
The interventions under investigation include: Placebo (DRUG), Lorecivivint (DRUG).
Who is sponsoring clinical trial NCT04520607?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.